This is the authors' abstract. We don't add key points for this paper.
The N′-dabcyl-N α-(9-fluorenylmethoxy)-carbonyllysine was prepared by reaction of lysine-Cu2+ complex with the N-hydroxysuccinimide (HOSu) activated ester of [4-(4'-dimethylamino)phenylazo]benzoic acid (dabcyl acid) followed by treatment with EDTA and acylation with Fmoc-OSu, and the N α-tert-butyloxycarbonyl-N′-dabcyllysine was prepared by reaction of N α-tert-butyloxycarbonyllysine with dabcyl-OSu.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: